Biased beta-agonists may provide better control of asthma and other obstructive lung diseases, drug discovery study shows

TAMPA, Fla. (Nov. 22, 2021) – Beta-agonists (β-agonists) are the only drugs that directly open narrowed airways and make it easier to breathe for millions of people with asthma, a chronic respiratory disease. These inhaled medications activate the b₂-adrenergic receptors (β₂AR) on airway smooth muscle cells and relax them, dilating airways and increasing air flow.

However, for a significant proportion of asthmatics, the effectiveness of existing β-agonists is insufficient to open tightly constricted airways and the clinical benefits realized appear to wane over time, leaving them constantly struggling with the disease.

“A lack of more effective therapies to treat or prevent shortness of breath is a major issue for patients with severe-to-moderate asthma,” said Stephen Liggett, MD, vice dean for research and a professor of medicine, molecular pharmacology and physiology, and biomedical engineering at the University of South Florida Health (USF Health) Morsani College of Medicine. “As regular use of β-agonists increases, the body becomes less sensitive to these bronchodilators.”

This process, known as tachyphylaxis or drug desensitization, contributes to insufficient asthma control, which leads to increased emergency department visits and hospitalizations — impacting the quality of life and extracting an economic toll in increased medical costs and missed days of work and school. Dr. Liggett’s laboratory works with collaborators across the country to understand the mechanisms of tachyphylaxis, with the aim of improving β-agonists.

Over the last three years, a multi-institutional research team led by USF Health studied 40 million compounds to identify those that activated β₂AR (β-agonists) without causing tachyphylaxis.The investigators found one such agonist, which was structurally distinct from all known traditional β-agonists. Their preclinical research suggests that a different class of β-agonists, known as biased agonists, offers promise for selectively treating asthma and other obstructive lung diseases. Such biased agonists offer a therapeutic option without causing the rapid turndown of these receptors (β₂AR) when the drug is used on an as-needed basis, or the even greater loss of effectiveness observed with chronic use.

The drug discovery study, published today in the Proceedings of the National Academy of Sciences of the United States (PNAS), was conducted by scientists with expertise in biochemistry, physiology, and computational biology. The team used molecular modeling driven by high speed, high-capacity supercomputers to define how this atypical agonist, named C1-S, works at the molecular level.

“This is the first β-agonist ever known to relax airway smooth muscle and treat asthma without any detectable tachyphylaxis and represents a significant breakthrough in asthma therapy,” said principal investigator Dr. Liggett, the PNAS paper’s senior author.

β2-adrenergic receptors are G protein-coupled receptors (GPCR), present in airway smooth muscle cells to mediate various functions. The existing β-agonists used to treat asthma are all unbiased. That means the drug equally favors activating a G-protein signaling pathway that promotes airway smooth muscle cell relaxation (thus easier breathing) as well as engaging a beta arrestin (β-arrestin) signaling pathway that leads to the unwanted outcome of tachyphylaxis.

“Beta-arrestin is a protein that upon interaction with the G protein-coupled receptor begins to uncouple (inhibit) the receptor from stimulating the clinically important signaling pathway we want to preserve,” Dr. Liggett explained. “With unbiased beta agonists you have these dueling signaling processes essentially competing with each other.”

Research is underway to design biased agonists to help alleviate pain without addiction and to better treat certain cardiovascular conditions with minimal side effects; however, no
GPCR-biased agonists are yet being developed for asthma.

The researchers approached this massive study with “no preconceived notions” about what compounds might work best, Dr. Liggett said. Among their key findings:

• Of the 40 million compounds screened, 12 agonists activated the target receptor (β₂AR), stimulating cyclic AMP production that causes airway smooth muscle relaxation. But only one of these 12 (C1-S) appeared to be strongly biased away from the β-arrestin signaling that limits airway smooth muscle response (and thus drug effectiveness) due to receptor desensitization.
   
• Through a series of biochemical experiments, the researchers verified for the first time that it was possible for an agonist to “split the signal” mediated by a G coupled-protein receptor (β₂AR). This split preferentially activates, or switches on, a signaling pathway beneficial for treating obstructive lung disease rather than a pathway believed to be physiologically harmful, Dr. Liggett said.
   
• In addition to measuring signaling at the cellular level, the researchers employed the magnetic twisting cytometry, a method pioneered by co-author Steven An, PhD, at Rutgers University that measures changes in human airway smooth muscle cell relaxation and contraction. All the biochemistry results correlated with the physiological response the researchers expected — relaxation of airway smooth muscle without desensitization.
   
• Computer modeling and docking was performed by investigators at Caltech (William Goddard III, PhD, and now graduate student Alina Tokmakova). These studies helped identify molecular contact points between the receptor and biased agonist C1-S; some of these binding sites had not been seen with any other agonist before and thus point to the basis of the properties of this unique drug. The collection of 40 million compounds was assembled and maintained by Marc Giulianotti, PhD, of Florida International University.

The researchers plan to evaluate the safety and efficacy of their lead drug candidate C1-S for potential use in humans, Dr. Liggett said.

“Everyday we see breakthrough asthma symptoms in patients using albuterol, a beta-2 receptor agonist that is the cornerstone of treatment. When exacerbated, these symptoms sometimes require hospitalization, use of a ventilator, and occasionally even result in death,” said Kathryn S. Robinett, MD, assistant professor of medicine at the University of Maryland School of Medicine’s Division of Pulmonary and Critical Care Medicine, who was not involved in the research. “A new class of beta-agonists that do not cause tachyphylaxis, like the one characterized in this study, could provide rapid relief and add a powerful tool to our belt in the treatment of asthma.”

The study’s co-lead authors were Donghwa Kim, PhD, of the USF Health Morsani College of Medicine, and Alina Tokmakova, currently a graduate student at University of California San Francisco.

The work was supported by grants from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

###
USF Health’s mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the Taneja College of Pharmacy, the School of Physical Therapy and Rehabilitation Sciences, the Biomedical Sciences Graduate and Postdoctoral Programs, and USF Health’s multispecialty physicians group. The University of South Florida is a high-impact global research university dedicated to student success. Over the past 10 years, no other public university in the country has risen faster in U.S. News and World Report’s national university rankings than USF. For more information, visit health.usf.edu